

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10517784	
	Filing Date		2004-12-13	
	First Named Inventor	Gideon Gross		
	Art Unit	1643		
	Examiner Name	RAWLINGS, STEPHEN L		
	Attorney Docket Number	GROSS32		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7414108	B2	2009-08-19	LAUS, REINER ET AL	
	2	6210662	B2	2001-04-03	LAUS, REINER ET AL	
	3	6194152	B1	2001-02-27	LAUS, REINER ET AL	
	4	6080409	A	2000-06-27	LAUS, REINER ET AL	
	5	5976546	A	1999-11-02	LAUS, REINER ET AL	
	6	7718762	B2	2010-05-18	COGGIN Jr., JOSEPH H. ET AL	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

1						
---	--	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	YU YIKY L et al., "Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells." Journal of Immunology 168: pages 3145-9 (2002);	<input type="checkbox"/>
	2	VAN DEN EYNDE BJ et al. "T cell defined tumor antigens" Current Opinion in Immunology Current Biology Ltd 9: pages 684-93 (1997);	<input type="checkbox"/>
	3	TAFURO et al. "Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2M fusion molecules" European Journal of Immunology 31: pages 440-9 (2001);	<input type="checkbox"/>
	4	WEN Y J et al. "Immunogenicity and cross-reactivity with idiotype IgA of VH CDR3 peptide in multiple myeloma." British Journal of Haematology 100: pages 464-8 (1998);	<input type="checkbox"/>
	5	JAMES L GULLEY et al "Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer." Cancer Immunol Immunother 59: pages 663-674 (2010);	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

6	SONIA E PEREZ et al. "A New Era in Anticancer Peptide Vaccines" Cancer 116: pages 2071-2080 (2010);	<input type="checkbox"/>
7	TAYLOR H. SCHREIBER et al. "Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art" Seminars in Immunology 22: pages 105-112 (2010);	<input type="checkbox"/>
8	MICHAL J. BESSER et al, "Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients" Clinical Cancer Research 16 (9): pages 2646-2655 (2010);	<input type="checkbox"/>
9	ERIC J. SMALL et al, "Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer" Journal of Clinical Oncology 24 (10): pages 3089-3094 (2006);	<input type="checkbox"/>
10	BONNIE TAYLOR-BLAKE et al, "Prostatic Acid Phosphatase Is Expressed in Peptidergic and Nonpeptidergic Nociceptive Neurons of Mice and Rats" PLoS ONE 5 (1): pages 1-5 (2010);	<input type="checkbox"/>
11	MARK J. ZYLKA et al, "Prostatic Acid Phosphatase Is an Ectonucleotidase and Suppresses Pain by Generating Adenosine" Neuron 60: pages 111-122 (2008);	<input type="checkbox"/>
12	"Sipuleucel-T: APC 8015, APC-8015, Prostate Cancer Vaccine – Dendreon" [No authors listed] Drugs in R&D 7 (3): pages. 197-201 (2006).	<input type="checkbox"/>
13	PAMER and CRESSWELL, Mechanisms of MHC Class I-Restricted Antigen Processing, Annu. Rev. Immunol., 16:323-58 (1998)	<input type="checkbox"/>
14	MARRACK et al., Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction, Annu. Rev. Immunol., 26:171-203 (2008)	<input type="checkbox"/>
15	MATSUI et al., Kinetics of T-cell Receptor Binding to Peptide/I-Ek Complexes: Correlation of the Dissociation Rate with T-Cell Responsiveness, Proc. Natl. Acad. Sci. USA, 91:12862-12866 (1994)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.